USA |NASDAQ |USD
| Report Date | Period Ending | EPS Forecast | Last Quarter's EPS | Last Year's EPS |
|---|---|---|---|---|
| Nov 8, 2021 | Sep 2021 | $-0.15 | $-0.20 | $0.62 |
| Report Date | Period Ending | Revenue Forecast | Last Quarter’s Revenue | Last Year’s Revenue |
|---|---|---|---|---|
| Nov 8, 2021 | Sep 2021 | $600.00K | $201.00K | $68.00K |
Baudax Bio, Inc's next earnings date is Monday, Nov 8, 2021 for the fiscal quarter ending Sep 2021.
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 2 | $-0.14 | $-0.15 | $-0.14 |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 1 | $-0.74 | $-0.74 | $-0.74 |
| Dec 2022 | 2 | $-0.49 | $-0.49 | $-0.49 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2021 | 0 / 0 | $-0.14 | $-0.16 | $-0.16 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2021 | 0 / 0 | $-0.74 | $-0.80 | $-0.80 |
| Dec 2022 | 0 / 0 | $-0.49 | $-0.51 | $-0.51 |
| Period End | # of Analysts | Revenue Forecast | Low Revenue Forecast | High Revenue Forecast |
|---|---|---|---|---|
| Dec 2021 | 2 | $1.25M | $700.00K | $1.80M |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 2 | $2.25M | $1.50M | $3.00M |
| Dec 2022 | 2 | $11.90M | $10.30M | $13.50M |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Nov 8, 2021 | Sep 2021 | $-0.15 | - | - |
| Aug 5, 2021 | Jun 2021 | $-0.19 | $-0.20 | -5.26% |
| May 5, 2021 | Mar 2021 | $-0.21 | $-0.27 | -28.57% |
| Feb 16, 2021 | Dec 2020 | $-0.62 | $-0.09 | 85.37% |
| Nov 9, 2020 | Sep 2020 | $-0.58 | $0.62 | 207.83% |
| Aug 10, 2020 | Jun 2020 | $-0.47 | $-1.72 | -269.89% |
| May 8, 2020 | Mar 2020 | $-0.91 | $-4.03 | -342.86% |
| Feb 13, 2020 | Dec 2019 | $-0.94 | $-0.78 | 17.02% |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Feb 16, 2021 | Dec 2020 | $-4.19 | $-5.22 | - |
| Feb 13, 2020 | Dec 2019 | $-3.60 | $-0.78 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Nov 8, 2021 | Sep 2021 | $600.00K | - | - |
| Aug 5, 2021 | Jun 2021 | $201.00K | $201.00K | 1.00% |
| May 5, 2021 | Mar 2021 | $630.00K | $198.00K | 0.31% |
| Feb 16, 2021 | Dec 2020 | $1.63M | $76.00K | 0.05% |
| Nov 9, 2020 | Sep 2020 | $1.00M | $68.00K | 0.07% |
| Aug 10, 2020 | Jun 2020 | $130.00K | $349.00K | 2.68% |
| May 8, 2020 | Mar 2020 | $0.00 | $0.00 | - |
| Feb 13, 2020 | Dec 2019 | $0.00 | $0.00 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Feb 16, 2021 | Dec 2020 | $2.03M | $493.00K | -75.71% |
| Feb 13, 2020 | Dec 2019 | $0.00 | $0.00 | - |
BXRX's next earnings date is Monday, Nov 8, 2021 for the fiscal quarter ending Sep 30, 2021.
According to 2 analysts, the average EPS estimation for Baudax Bio, Inc's next quarterly earnings is $-0.15, with a low EPS estimation of $-0.16, and a high estimation of $-0.15.
Over the last 1 month, EPS estimates have seen 0 upward revisions and 0 downward. The EPS 1 month trend is $-0.15, the last 2 month trend is $-0.20, and the 3 month trend is $-0.20.
Based on 3 analysts, the average revenue estimation is $600.00K, with a low revenue estimation of $400.00K, and a high estimation of $800.00K.
Baudax Bio, Inc's previous earnings date was Aug 5, 2021 for its fiscal quarter ended Jun 30, 2021.
BXRX's earnings per share (EPS) was $-0.20, missing the consensus analysts forecast of $-0.19 by -5.26%.
The EPS was higher than the previous fiscal quarter (Mar 2021) by -25.93%, and higher than the same period a year before (Jun 2020) by -88.37%.
Revenues were $201.00K, better than the forecast of $201.00K by 0.00%, up by 1.52% from the previous quarter , and down by -42.41% from the same period last year.
The company reported a net income of $-15.33M.Free cash flow for the quarter was $-24.13M , compared to $-14.08M last quarter and $-11.31M a year before.
BXRX ended the quarter with $8.07M in total debt, a decrease of -13.94% compared to the previous quarter, and a decrease of -7.15% compared to the same quarter a year before.
Baudax Bio, Inc's previous annual earnings date was Feb 16, 2021 for its fiscal year ended Dec 31, 2020.
BXRX's earnings per share (EPS) was $-5.22, missing the consensus analysts forecast of $-4.19 by 24.58% , and lower than the previous year's EPS (Dec 2019) by 569.23%.
Revenues were $493.00K.
The company reported a net income of $-76.10M.
Baudax Bio, Inc reported a free cash flow of $-44.70M for its fiscal year, compared to $-51.53M a year ago.
The company ended the fiscal year with $9.48M in total debt, an increase of 1127.04% compared to the previous year.
Get a weekly snapshot of one new investment idea from stock exchanges worldwide.
